Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
Saad F, Armstrong AJ, Oya M, Vianna K, Özgüroğlu M, Gedye C, Buchschacher GL Jr, Lee JY, Emmenegger U, Navratil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Kim J, Oscroft E, Barker L, Degboe A, Clarke NW. Saad F, et al. Among authors: emmenegger u. Eur Urol Oncol. 2024 Apr 5:S2588-9311(24)00082-8. doi: 10.1016/j.euo.2024.03.006. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38582650 Free article.
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Chi KN, et al. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23. J Clin Oncol. 2023. PMID: 36952634 Free PMC article. Clinical Trial.
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
Yu EY, Berry WR, Gurney H, Retz M, Conter HJ, Laguerre B, Fong PCC, Ferrario C, Todenhöfer T, Gravis G, Piulats JM, Emmenegger U, Shore ND, Romano E, Mourey L, Li XT, Poehlein CH, Schloss C, Appleman LJ, de Bono JS. Yu EY, et al. Among authors: emmenegger u. Eur Urol Oncol. 2024 Jun;7(3):509-518. doi: 10.1016/j.euo.2023.10.008. Epub 2023 Nov 7. Eur Urol Oncol. 2024. PMID: 37940446 Free article. Clinical Trial.
Editorial Comment.
Smoragiewicz M, Emmenegger U. Smoragiewicz M, et al. Among authors: emmenegger u. J Urol. 2023 Jun;209(6):1130. doi: 10.1097/JU.0000000000003370.02. Epub 2023 Mar 23. J Urol. 2023. PMID: 36950912 No abstract available.
TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer (TOPCOP3): A pilot randomized controlled trial and process evaluation.
Alibhai SMH, Puts M, Jin R, Godhwani K, Antonio M, Abdallah S, Feng G, Krzyzanowska MK, Soto-Perez-de-Celis E, Papadopoulos E, Mach C, Nasiri F, Sridhar SS, Glicksman R, Moody L, Bender J, Clarke H, Matthew A, McIntosh D, Klass W, Emmenegger U. Alibhai SMH, et al. Among authors: emmenegger u. J Geriatr Oncol. 2024 Mar 22:101750. doi: 10.1016/j.jgo.2024.101750. Online ahead of print. J Geriatr Oncol. 2024. PMID: 38521641 Free article.
Understanding the incidence, duration, and severity of symptoms through daily symptom monitoring among frail and non-frail older patients receiving metastatic prostate cancer treatments.
Parthipan M, Feng G, Breunis H, Timilshina N, Emmenegger U, Hansen A, Tomlinson G, Matthew A, Clarke H, Santa Mina D, Soto-Perez-de-Celis E, Puts M, Alibhai SMH. Parthipan M, et al. Among authors: emmenegger u. J Geriatr Oncol. 2024 Apr;15(3):101720. doi: 10.1016/j.jgo.2024.101720. Epub 2024 Feb 13. J Geriatr Oncol. 2024. PMID: 38350343 Free article.
Daily physical activity monitoring in older adults with metastatic prostate cancer on active treatment: Feasibility and associations with toxicity.
Feng G, Parthipan M, Breunis H, Timilshina N, Soto-Perez-de-Celis E, Mina DS, Emmenegger U, Finelli A, Krzyzanowska MK, Clarke H, Puts M, Alibhai SMH. Feng G, et al. Among authors: emmenegger u. J Geriatr Oncol. 2023 Sep;14(7):101576. doi: 10.1016/j.jgo.2023.101576. Epub 2023 Jul 6. J Geriatr Oncol. 2023. PMID: 37421787
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. Fizazi K, et al. Among authors: emmenegger u. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. N Engl J Med. 2023. PMID: 36795891 Free PMC article. Clinical Trial.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Shore ND, et al. Among authors: emmenegger u. Oncologist. 2024 Feb 23:oyae019. doi: 10.1093/oncolo/oyae019. Online ahead of print. Oncologist. 2024. PMID: 38394384 Free article.
Symptom experiences of older adults during treatment for metastatic prostate cancer: A qualitative investigation.
Parthipan M, Feng G, Toledano N, Donison V, Breunis H, Sudharshan A, Emmenegger U, Finelli A, Warde P, Soto-Perez-de-Celis E, Krzyzanowska M, Matthew A, Clarke H, Mina DS, Alibhai SMH, Puts M. Parthipan M, et al. Among authors: emmenegger u. J Geriatr Oncol. 2023 Jan;14(1):101397. doi: 10.1016/j.jgo.2022.10.012. Epub 2022 Oct 28. J Geriatr Oncol. 2023. PMID: 36988104
121 results